Moolec Science SA (MLEC) Balance Sheet

NASDAQ: MLECAssets, liabilities, debt and equity over 5 years.

MLEC balance sheet, FY2025

June 30, 2025 · U.S. dollars

$204.7M assets = $287.6M liabilities + −$82.9M equity

What it owns$204.7MCash & ST investments: $9.0M (4.4%)Receivables: $19.9M (9.7%)Receivables $19.9MInventory: $2.2M (1.1%)Other current: $11,835 (0.0%)PP&E: $3.4M (1.7%)Goodwill & intangibles: $75.3M (36.8%)Goodwill & intangibles$75.3M · 37%LT investments: $94.1M (46.0%)LT investments$94.1M · 46%Other non-current: $664,493 (0.3%)=How it is financed$287.6MCurrent liabilities: $236.1M (82.1%)Current liabilities$236.1M · 82%Long-term debt: $19.6M (6.8%)Long-term debt $19.6MOther LT liabilities: $31.9M (11.1%)$31.9M

Liabilities exceed assets: shareholders’ equity is negative (−$82.9M).

Both columns are drawn to the same scale: what MLEC owns equals what it owes plus shareholders’ equity. Hover a block for its value.

MLEC financial health

Current ratio0.13
Tight · current assets cover current liabilities 0.13×
Equity / assets−32.2%
Thin equity · of assets funded by shareholders
Cash / debt3.7%
Low cash cover · cash & short-term investments vs total debt
Goodwill & intangibles36.8%
Acquisition-heavy · of total assets

Descriptive bands, not a rating. Fiscal FY2025.

MLEC balance sheet trends, FY2021–FY2025

Moolec Science SA balance sheet trends
MetricTrendThenLatestChange
Total assets$138.6MFY2021$204.7MFY2025+10.2%/yr
Total liabilities$4.5MFY2021$287.6MFY2025+182.6%/yr
Shareholders’ equity$134.1MFY2021−$66.0MFY2025—
Cash & short-term investments$337,603FY2021$9.0MFY2025+127.4%/yr
Total debt$125,000FY2021$246.9MFY2025+566.6%/yr
Net cash (debt)$212,603FY2021−$237.9MFY2025−$238.1M
Working capital−$280,157FY2021−$204.9MFY2025−$204.6M
Book value per share$115.79FY2021−$153.11FY2025—
Current ratio0.67FY20210.13FY2025−0.54
Debt / equity0.00FY20212.15FY2024+2.15
Shares outstanding1.2MFY2021431KFY2025−21.9%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

MLEC assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

MLEC liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

MLEC debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

MLEC balance sheet

Moolec Science SA annual balance sheet
FY2025FY2024FY2023FY2022FY2021
Assets
Cash & short-term investments$9.0M$5.4M$2.8M$1.1M$337,603
Cash & equivalents$767,919$5.4M$2.5M$1.1M$337,603
Short-term investments$8.3M$14.7M$306,034$0—
Receivables$19.9M$1.5M$1.7M$0$289,888
Inventory$2.2M$6.3M$465,748$0$0
Other current assets$11,835$596,938$341,107$2,061$0
Total current assets$31.2M$13.7M$5.3M$1.1M$581,697
Property, plant & equipment (net)$3.4M$1.6M$1.2M$8,918$10,617
Goodwill & intangible assets$75.3M$9.2M$8.8M$4.6M$4.6M
Long-term investments$94.1M$93.0M$0$0$0
Other non-current assets$664,493$0$8.8M$0$133.4M
Total assets$204.7M$34.8M$24.1M$5.7M$138.6M
Liabilities
Accounts payable$6.5M$873,534$2.3M$164,127$587,658
Short-term debt$227.3M$2.7M$2.5M$125,000$125,000
Deferred revenue$1,260—$6.6M−$125,000−$300,000
Total current liabilities$236.1M$8.2M$12.6M$4.1M$861,854
Long-term debt$19.6M$11.7M$99,046$0$0
Lease obligations$117,463$421,887$0——
Other long-term liabilities$31.9M$8.1M$1.2M$2.2M$3.6M
Total liabilities$287.6M$28.0M$13.9M$4.1M$4.5M
Shareholders' equity
Common stock & paid-in capital$1.1M$385,641$375,641$310,000$129.1M
Retained earnings (deficit)−$110.3M−$65.9M−$58.6M−$6.8M−$828,078
Accumulated other comprehensive income$3.9M$125,709$18,112——
Minority interest−$16.9M$248.8M———
Total shareholders' equity−$66.0M$6.8M$10.1M$1.6M$134.1M
Key figures
Total debt$246.9M$14.7M$2.6M$125,000$125,000
Net cash (debt)−$237.9M−$9.3M$188,418$956,808$212,603
Working capital−$204.9M$5.6M−$7.3M−$3.0M−$280,157
Tangible book value−$141.2M−$2.4M$1.3M−$3.0M$129.5M
Book value per share−$153.11$2.66$4.40$0.64$115.79
Shares outstanding431K2.6M2.3M2.5M1.2M
Current ratio0.131.690.420.270.67
Quick ratio0.120.840.360.260.73
Debt / equity—2.150.260.080.00
Equity / assets−32.2%19.6%42.0%28.2%96.7%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 29, 2025); data from EODHD.

MLEC financial position

At the end of fiscal 2025 (June 30, 2025), Moolec Science had total assets of $204.7 million (up 488.5% from a year earlier), total liabilities of $287.6 million and shareholders' equity of -$66.0 million. It held $9.0 million in cash and short-term investments against $246.9 million of debt, net debt of $237.9 million. Its current ratio was 0.13. In the latest quarter (ended March 31, 2026) total assets were $103.4 million and equity $9.2 million.

Related: MLEC income statement, MLEC cash flow statement, MLEC key metrics. See the MLEC stock overview for the latest quote and news.

MLEC balance sheet FAQ

What are Moolec Science's total assets?

Moolec Science reported total assets of $204.7 million at the end of fiscal 2025 (June 30, 2025), compared with $34.8 million a year earlier.

How much debt does Moolec Science have?

Moolec Science had $246.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.

How much cash does Moolec Science have?

Moolec Science held $9.0 million in cash and short-term investments at the end of fiscal 2025; with $246.9 million of debt that is net debt of $237.9 million.

What is Moolec Science's book value?

Moolec Science's shareholders' equity (book value) was -$66.0 million at the end of fiscal 2025, or −$153.11 per share.

What is Moolec Science's current ratio?

Moolec Science had current assets of $31.2 million and current liabilities of $236.1 million, a current ratio of 0.13 (current liabilities exceed current assets).

How much goodwill does Moolec Science have?

Moolec Science carried $75.3 million of goodwill and intangible assets, 36.8% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet